Akebia Therapeutics, Inc. (AKBA)

Akebia Therapeutics' Chief Commercial Officer Nik Grund will participate in a Fireside Chat at the 4th Annual Kidney Virtual Conference on July 14, 2025, discussing the company's kidney disease research and developments.

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 0% and 20.72%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Shares of RH (NYSE: RH) rose sharply in today’s pre-market trading following the release of quarterly results. RH posted weaker-than-expected results for its fourth quarter, but issued upbeat forecast. The company said it sees full-year 2024 demand growth of 12% to 14% and revenue growth of 8% to 10% on a year-over-year basis, according to data from Benzinga Pro. RH shares jumped 9.4% to $324.99 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers Avalo Therapeutics, Inc. (NASDAQ: AVTX) rose 256.6% to $16.94 in pre-market trading after the company announced it acquired a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio. Binah Capital Group, Inc. (NASDAQ: BCG) gained 149% to $23.65 in pre-market trading after dipping more than 20% on Wednesday. Kidpik Corp. (NASDAQ: PIK) gained 49.5% to $4.89 in pre-market trading. Kidpik recently regained compliance with the Nasdaq minimum bid price requirement. Kintara Therapeutics, Inc. (NASDAQ: KTRA) shares rose 36.3% to $0.1220 in pre-market ...

Analysts say these are penny stocks to buy but are they worth the risk? The post 3 Penny Stocks To Buy According To Analysts, Targets Up To 1,494% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Investors head into next week with the debt ceiling crisis resolved for the near term.